TITLE

The complicated path to true causes of disease: role of nuclear factor κB in inflammatory bowel disease

AUTHOR(S)
Schreiber, S.
PUB. DATE
April 2005
SOURCE
Gut;Apr2005, Vol. 54 Issue 4, p444
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
This article focuses on the role of nuclear factor kappa B (NFkB) in inflammatory bowel disease. NFkB was discovered as a transcription factor some 15 years ago. Since then the protein has been linked to early pathophysiological events in a host of inflammatory conditions. In Crohn's disease, mechanistic data have been generated in an animal model that undoubtedly demonstrated that activation of NFkB is intimately linked to mucosal inflammation and destruction. The use of antisense constructs to silence NFkB greatly improved inflammatory lesions in the murine interleukin 10 knockout model of inflammatory bowel disease (IBD) and also resolved inflammatory events in human intestinal cells from patients with IBD.
ACCESSION #
16556640

 

Related Articles

  • A DOUBLE BLIND, PLACEBO CONTROLLED RANDOMISED TRIAL OF CURCUMIN EXTRACT IN THE TREATMENT OF STEROID DEPENDENT INFLAMMATORY BOWEL DISEASE. Atkinson, R.J.; Hunter, J.O. // Gut;Apr2003 Supplement 1, Vol. 52, pA63 

    Introduction: Nuclear factor kappa B (NFkB) is a pro-inflammatory transcription factor which plays an integral part in the pathogenesis of inflammatory bowel disease (IBD). Curcumin has anti-inflammatory properties through prevention of NFkB activation and is effective in the TNBS model of...

  • Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. Visekruna, Alexander; Joeris, Thorsten; Seidel, Daniel; Kroesen, Anjo; Loddenkemper, Christoph; Zeitz, Martin; Kaufmann, Stefan H. E.; Schmidt-Ullrich, Ruth; Steinhoff, Ulrich // Journal of Clinical Investigation;Dec2006, Vol. 116 Issue 12, p3195 

    Enhanced NF-kappaB activity is involved in the pathology of both forms of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Here we analyzed the mechanism of proteasome-mediated NF-kappaB activation in CD and UC. Our studies demonstrate that the subunit...

  • Inflammatory disease: Local therapy for inflammatory bowel disease. Brazil, Melanie // Nature Reviews Drug Discovery;Dec2005, Vol. 4 Issue 12, p958 

    The article reports on the successful treatment of both murine models of ulcerative colitis and Crohn's disease with locally or systematically delivered nuclear factor-;A. The authors showed that intrarectal or intraperitoneal administration of decoy oligodeoxynucleotides, which were...

  • The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Moschen, A. R.; Kaser, A.; Enrich, B.; Ludwiczek, O.; Gabriel, M.; Obrist, P.; Wolf, A. M.; Tilg, H. // Gut;Apr2005, Vol. 54 Issue 4, p479 

    Background and aims: A substantial proportion of patients with inflammatory bowel disease (IBD) develops osteopenia and osteoporosis in the course of disease. Recent data from a mouse model of colitis suggest that the receptor activator of nuclear factor kappa B (RANKL)/osteoprotegerin (OPG)...

  • TFT Adds NF-kappa B Decoy Program.  // Bioworld Week;6/9/2008, Vol. 16 Issue 23, p4 

    The article reports that Transcription Factor Therapeutics Inc. (TFT) has considered rights to NF-kappa B Decoy program including a $114 million deal from Anesiva Inc. in Irvine, California. It states that TFT will get intellectual property pertaining to NF-kappa B, a transcription factor that...

  • Inflammatory bowel disease I.  // Gut;Jul2012 Supplement, Vol. 61, pA165 

    The article presents abstracts on medical topics of Great Britain which include inflammatory bowel diseases, the role of Nuclear Factor kappa B and the inducing of colitis with dextran sodium sulfate (DSS).

  • Tumorigenesis: Inflammatory debate. McCarthy, Nicola // Nature Reviews Cancer;Oct2004, Vol. 4 Issue 10, p753 

    The article discusses inflammatory diseases in patients. The increased risk of tumor occurrence in patients with chronic inflammatory diseases has long been reported. Patients with the inflammatory bowel disease ulcerative colitis are treated with non-steroidal anti-inflammatory drugs to reduce...

  • TLR5 Risk-Associated Haplotype for Canine Inflammatory Bowel Disease Confers Hyper-Responsiveness to Flagellin. Kathrani, Aarti; Holder, Angela; Catchpole, Brian; Alvarez, Lorena; Simpson, Kenneth; Werling, Dirk; Allenspach, Karin // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Single nucleotide polymorphisms (SNP) in the TLR5 gene have been associated with human inflammatory bowel disease (IBD) and animal models of this disease. We recently demonstrated a significant association between three nonsynonymous SNPs in the canine TLR5 gene and IBD in German shepherd dogs...

  • Effects of recombinant human intestinal trefoil factor on trinitrobenzene sulphonic acid induced colitis in rats. Li, Jin; Zhou, Rui; He, Wen-cheng; Xia, Bing // Molecular Biology Reports;Oct2011, Vol. 38 Issue 7, p4787 

    Intestinal trefoil factor (ITF) has been proved to be effective in treatment of ulcerative colitis. However, the mechanisms of it remain unclear. In this study, we observed the effects of combined treatment with 5-aminosalicylic acid (5-ASA) and recombinant human ITF (rhITF) on the expression of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics